JP2023538030A5 - - Google Patents
Info
- Publication number
- JP2023538030A5 JP2023538030A5 JP2023511588A JP2023511588A JP2023538030A5 JP 2023538030 A5 JP2023538030 A5 JP 2023538030A5 JP 2023511588 A JP2023511588 A JP 2023511588A JP 2023511588 A JP2023511588 A JP 2023511588A JP 2023538030 A5 JP2023538030 A5 JP 2023538030A5
- Authority
- JP
- Japan
- Prior art keywords
- weight
- oral contraceptive
- composition according
- oral
- contraceptive composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20382753.0A EP3954364A1 (en) | 2020-08-14 | 2020-08-14 | New modified release oral contraceptive composition |
| EP20382753.0 | 2020-08-14 | ||
| PCT/EP2021/072584 WO2022034209A1 (en) | 2020-08-14 | 2021-08-13 | New modified release oral contraceptive composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023538030A JP2023538030A (ja) | 2023-09-06 |
| JP2023538030A5 true JP2023538030A5 (enExample) | 2024-08-13 |
Family
ID=72145348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023511588A Pending JP2023538030A (ja) | 2020-08-14 | 2021-08-13 | 新規の調節放出性経口避妊用組成物 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US12409141B2 (enExample) |
| EP (2) | EP3954364A1 (enExample) |
| JP (1) | JP2023538030A (enExample) |
| KR (1) | KR20230067614A (enExample) |
| CN (1) | CN116322701A (enExample) |
| AU (1) | AU2021325372A1 (enExample) |
| BR (1) | BR112023002654A2 (enExample) |
| CA (1) | CA3191326A1 (enExample) |
| CL (1) | CL2023000450A1 (enExample) |
| CO (1) | CO2023002874A2 (enExample) |
| CR (1) | CR20230127A (enExample) |
| DO (1) | DOP2023000029A (enExample) |
| EC (1) | ECSP23016038A (enExample) |
| IL (1) | IL300578A (enExample) |
| JO (1) | JOP20230032A1 (enExample) |
| MX (1) | MX2023001868A (enExample) |
| PE (1) | PE20231378A1 (enExample) |
| PY (1) | PY2168235A (enExample) |
| UY (1) | UY39379A (enExample) |
| WO (1) | WO2022034209A1 (enExample) |
| ZA (1) | ZA202303273B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20260021110A1 (en) * | 2024-07-18 | 2026-01-22 | Chemo Research, S.L. | Methods of oral contraception by controlled release of dienogest and ethynyl estradiol |
| WO2026146125A1 (en) | 2024-12-30 | 2026-07-09 | Chemo Research, S.L. | Treatment of hirsutism, polycystic ovarian syndrome and other associated conditions |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5340585A (en) | 1991-04-12 | 1994-08-23 | University Of Southern California | Method and formulations for use in treating benign gynecological disorders |
| WO1997004752A1 (en) * | 1995-07-26 | 1997-02-13 | Duramed Pharmaceuticals, Inc. | Pharmaceutical compositions of conjugated estrogens and methods for their use |
| US7589082B2 (en) | 2003-06-13 | 2009-09-15 | Skendi Finance Ltd | Pharmaceutical formulation for contraception and hormone-replacement therapy |
| EP1690529A1 (de) | 2005-02-15 | 2006-08-16 | Schering AG | Feste perorale Arzneiform zur Kontrazeption, die Dienogest und Ethinylestradiol enthält |
| DK1848406T3 (da) * | 2005-02-15 | 2008-09-15 | Jenapharm Gmbh | Fast, penoral lægemiddelform til kontraception, der indeholder dienogest og ethynylestradiol |
| DE102005034498A1 (de) * | 2005-07-20 | 2007-01-25 | Grünenthal GmbH | Orale Kontrazeption mit Trimegeston |
| TW201008569A (en) * | 2008-08-08 | 2010-03-01 | Bayer Schering Pharma Ag | Progestin-containing drug delivery system |
-
2020
- 2020-08-14 EP EP20382753.0A patent/EP3954364A1/en not_active Withdrawn
-
2021
- 2021-08-13 US US18/021,165 patent/US12409141B2/en active Active
- 2021-08-13 WO PCT/EP2021/072584 patent/WO2022034209A1/en not_active Ceased
- 2021-08-13 PY PY202102168235A patent/PY2168235A/es unknown
- 2021-08-13 PE PE2023000270A patent/PE20231378A1/es unknown
- 2021-08-13 AU AU2021325372A patent/AU2021325372A1/en active Pending
- 2021-08-13 JP JP2023511588A patent/JP2023538030A/ja active Pending
- 2021-08-13 IL IL300578A patent/IL300578A/en unknown
- 2021-08-13 EP EP21762678.7A patent/EP4196098A1/en active Pending
- 2021-08-13 CN CN202180070759.5A patent/CN116322701A/zh active Pending
- 2021-08-13 CR CR20230127A patent/CR20230127A/es unknown
- 2021-08-13 UY UY0001039379A patent/UY39379A/es unknown
- 2021-08-13 MX MX2023001868A patent/MX2023001868A/es unknown
- 2021-08-13 KR KR1020237008915A patent/KR20230067614A/ko active Pending
- 2021-08-13 BR BR112023002654A patent/BR112023002654A2/pt unknown
- 2021-08-13 CA CA3191326A patent/CA3191326A1/en active Pending
-
2023
- 2023-02-10 DO DO2023000029A patent/DOP2023000029A/es unknown
- 2023-02-13 JO JOJO/P/2023/0032A patent/JOP20230032A1/ar unknown
- 2023-02-14 CL CL2023000450A patent/CL2023000450A1/es unknown
- 2023-03-02 ZA ZA2023/03273A patent/ZA202303273B/en unknown
- 2023-03-06 EC ECSENADI202316038A patent/ECSP23016038A/es unknown
- 2023-03-09 CO CONC2023/0002874A patent/CO2023002874A2/es unknown
-
2024
- 2024-05-09 US US18/660,021 patent/US12409142B2/en active Active
-
2025
- 2025-08-07 US US19/293,837 patent/US20260027058A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016368622B2 (en) | Pharmaceutical composition comprising a potent inhibitor of URAT1 | |
| US20040166159A1 (en) | Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa | |
| US8617601B2 (en) | Methods and formulations for making pharmaceutical compositions containing bupropion | |
| US20030224045A1 (en) | Combination immediate release sustained release levodopa/carbidopa dosage forms | |
| EP2494964A1 (en) | Combinations of valsartan and amlodipine | |
| MXPA06006677A (es) | Formas de dosis de torasemida de liberacion sostenida. | |
| CN1762357B (zh) | 一种莫西沙星口服药物制剂及其制备方法 | |
| EP2696857A1 (en) | Pharmaceutical composition comprising bosentan | |
| CN113712929B (zh) | 一种mt-1207盐酸盐缓释制剂及其制备方法与应用 | |
| WO2015011161A1 (en) | Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation | |
| WO2009027786A2 (en) | Matrix dosage forms of varenicline | |
| AU2006274565B2 (en) | Novel controlled release compositions of selective serotonin reuptake inhibitors | |
| CN103768034A (zh) | 一种含有盐酸安非他酮的缓控释固体组合物 | |
| TWI733299B (zh) | 普加巴林的持續-釋放配方 | |
| JP3007387B2 (ja) | 徐放性製剤用基剤粉末 | |
| TW201201800A (en) | A pharmaceutical controlled release composition of losartan | |
| JP7857044B2 (ja) | シプロフロキサシン及びセレコキシブを含む組成物 | |
| Agiba | Modulatory effect of polymer type and concentration on drug release from sustained release matrix tablets of ranolazine: A comparative release kinetic study | |
| Raffick et al. | Preparation and evaluationof in-vitro release kinetics of novel bilayer metoprolol succinate as sustained release and amlodipine besylate as immediat release tablets | |
| RU2584653C2 (ru) | Фармацевтическая композиция с пролонгированным высвобождением с антипсихотической активностью и способы её получения | |
| WO2024022382A1 (zh) | 渗透泵控释制剂、渗透泵控释组合物、制备方法和应用 | |
| US20040228918A1 (en) | Granule modulating hydrogel system | |
| JP2003048828A (ja) | 有効成分として塩酸ビュープロピオンを含む、改良型放出医薬品組成物 | |
| US20050074491A1 (en) | Universal controlled-release composition | |
| TWI377957B (en) | Methods and formulations for making pharmaceutical compositions containing bupropion |